BNP Paribas Financial Markets’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-67,814
| Closed | -$1.26M | – | 4141 |
|
|
2023
Q3 | $1.26M | Sell |
67,814
-20,888
| -24% | -$236K | ﹤0.01% | 2180 |
|
|
2023
Q2 | $981K | Sell |
88,702
-32,269
| -27% | -$450K | ﹤0.01% | 2211 |
|
|
2023
Q1 | $1.62M | Buy |
120,971
+47,169
| +64% | +$816K | ﹤0.01% | 1973 |
|
|
2022
Q4 | $913K | Sell |
73,802
-45,641
| -38% | -$646K | ﹤0.01% | 2216 |
|
|
2022
Q3 | $1.67M | Buy |
119,443
+109,394
| +1,089% | +$1.76M | ﹤0.01% | 2088 |
|
|
2022
Q2 | $139K | Sell |
10,049
-10,873
| -52% | -$174K | ﹤0.01% | 3237 |
|
|
2022
Q1 | $340K | Sell |
20,922
-33,337
| -61% | -$522K | ﹤0.01% | 2933 |
|
|
2021
Q4 | $884K | Buy |
54,259
+40,947
| +308% | +$690K | ﹤0.01% | 2677 |
|
|
2021
Q3 | $198K | Buy |
13,312
+163
| +1% | +$2.61K | ﹤0.01% | 3043 |
|
|
2021
Q2 | $263K | Sell |
13,149
-24,339
| -65% | -$483K | ﹤0.01% | 2797 |
|
|
2021
Q1 | $865K | Sell |
37,488
-120,010
| -76% | -$3.35M | ﹤0.01% | 2229 |
|
|
2020
Q4 | $3.89M | Buy |
157,498
+134,775
| +593% | +$4.47M | 0.01% | 1283 |
|
|
2020
Q3 | $942K | Sell |
22,723
-6,501
| -22% | -$299K | ﹤0.01% | 1843 |
|
|
2020
Q2 | $1.4M | Sell |
29,224
-10,110
| -26% | -$781K | ﹤0.01% | 1645 |
|
|
2020
Q1 | $2.48M | Buy |
39,334
+25,928
| +193% | +$2.33M | 0.01% | 1362 |
|
|
2019
Q4 | $1.66M | Sell |
13,406
-529
| -4% | -$47.4K | ﹤0.01% | 1762 |
|
|
2019
Q3 | $925K | Sell |
13,935
-5,871
| -30% | -$394K | ﹤0.01% | 1890 |
|
|
2019
Q2 | $1.58M | Buy |
19,806
+7,775
| +65% | +$696K | ﹤0.01% | 1577 |
|
|
2019
Q1 | $1.35M | Buy |
12,031
+4,175
| +53% | +$456K | ﹤0.01% | 1574 |
|
|
2018
Q4 | $792K | Sell |
7,856
-1,244
| -14% | -$129K | ﹤0.01% | 1670 |
|
|
2018
Q3 | $1.15M | Sell |
9,100
-2,311
| -20% | -$245K | ﹤0.01% | 1705 |
|
|
2018
Q2 | $957K | Sell |
11,411
-978
| -8% | -$71.6K | ﹤0.01% | 1760 |
|
|
2018
Q1 | $762K | Sell |
12,389
-2,490
| -17% | -$150K | ﹤0.01% | 1923 |
|
|
2017
Q4 | $869K | Buy |
14,879
+9,456
| +174% | +$596K | ﹤0.01% | 2086 |
|
|
2017
Q3 | $315K | Sell |
5,423
-612
| -10% | -$65.9K | ﹤0.01% | 2221 |
|
|
2017
Q2 | $731K | Buy |
6,035
+1,029
| +21% | +$119K | ﹤0.01% | 1698 |
|
|
2017
Q1 | $566K | Buy |
5,006
+990
| +25% | +$116K | ﹤0.01% | 1670 |
|
|
2016
Q4 | $436K | Sell |
4,016
-352
| -8% | -$41.9K | ﹤0.01% | 1767 |
|
|
2016
Q3 | $719K | Buy |
4,368
+267
| +7% | +$42.1K | ﹤0.01% | 1043 |
|
|
2016
Q2 | $585K | Sell |
4,101
-855
| -17% | -$125K | ﹤0.01% | 1436 |
|
|
2016
Q1 | $637K | Sell |
4,956
-2,504
| -34% | -$296K | ﹤0.01% | 1132 |
|
|
2015
Q4 | $1.11M | Buy |
7,460
+2,300
| +45% | +$389K | ﹤0.01% | 1085 |
|
|
2015
Q3 | $856K | Buy |
5,160
+731
| +17% | +$161K | ﹤0.01% | 1096 |
|
|
2015
Q2 | $1.07M | Buy |
4,429
+3,510
| +382% | +$935K | ﹤0.01% | 1101 |
|
|
2015
Q1 | $259K | Buy |
919
+903
| +5,644% | +$196K | ﹤0.01% | 1485 |
|
|
2014
Q4 | $2.5K | Sell |
16
-484
| -97% | -$89.4K | ﹤0.01% | 1855 |
|
|
2014
Q3 | $118K | Buy |
500
+477
| +2,074% | +$122K | ﹤0.01% | 2093 |
|
|
2014
Q2 | $5.44K | Buy |
23
+5
| +28% | +$1.32K | ﹤0.01% | 2541 |
|
|
2014
Q1 | $4.75K | Sell |
18
-79
| -81% | -$26.7K | ﹤0.01% | 2416 |
|
|
2013
Q4 | $6.62K | Buy |
+97
| New | +$5.61K | ﹤0.01% | 2916 |
|
BNP Paribas Financial Markets's ICPT Position: Q4 2023 in Review
BNP Paribas Financial Markets sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 67,814 shares — an estimated $1.26M sold.
BNP Paribas Financial Markets first reported a position in ICPT in Q4 2013 and held it in 40 quarters. The position peaked at $3.89M in Q4 2020. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- BNP Paribas Financial Markets reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- BNP Paribas Financial Markets sold 67,814 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.26M.
- BNP Paribas Financial Markets first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 40 quarters.
- BNP Paribas Financial Markets's Intercept Pharmaceuticals, Inc. position peaked at $3.89M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2023, filed 7 Feb 2024.